Intended to Maximize Stakeholder Value Through Structured Process Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema... Read More

Presentations Highlight the Versatility of Clearside’s SCS Microinjector ® Platform for the Treatment of Multiple Retinal Diseases CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of... Read More

XIPERE Now Approved for Use in Multiple Global Markets Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector ® ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space... Read More

Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations ALPHARETTA, Ga., July 17, 2025 (GLOBE NEWSWIRE) --... Read More

Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through... Read More

ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast... Read More

Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing Multiple Milestones Achieved by Commercial and Development Partners Use of Suprachoroidal Drug Delivery Featured in Over 15 Presentations at Major Ophthalmic Medical Meetings This Year ALPHARETTA, Ga., May 14,... Read More

ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that six presentations related to the Company’s lead program, CLS-AX (axitinib injectable suspension), and suprachoroidal drug delivery platform were... Read More

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not... Read More

ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that management will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 1:00 p.m. ET. A link to the live and archived webcast may be... Read More

ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate... Read More

Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD Asia-Pacific Partner’s New Drug Application for ARCATUS ® (XIPERE ® ) for Uveitic Macular Edema Accepted for Regulatory Review in China Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside’s SCS Microinjector ® Management to Host... Read More

Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases SCS Microinjector ® Provides Targeted and Compartmentalized Delivery of Therapeutics Directly to the Retina ALPHARETTA, Ga., March 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the... Read More

Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of... Read More

ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets.... Read More

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of... Read More

ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), reported that Arctic Vision’s New Drug Application (NDA) for ARCATUS ® for the treatment of uveitic macular edema (UME) has been formally accepted for review by the... Read More

ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting.... Read More

ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, will participate in a... Read More

Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial CLS-AX Targets Flexible Dosing of Biologics with Duration of Tyrosine Kinase Inhibitors ALPHARETTA, Ga., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the... Read More

ARCATUS ® , Branded as XIPERE ® in the U.S., is the First Globally Approved Suprachoroidal Therapy Continued Global Expansion of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector ® ALPHARETTA, Ga., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye... Read More

ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the official journal of The Royal College of Ophthalmologists, Eye , published a summary of critical insights into drug development and regulatory processes based on a... Read More

Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside’s Pipeline Programs and Suprachoroidal Delivery Technology Oral Presentations Delivered on ODYSSEY Wet AMD Topline Results ALPHARETTA, Ga., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a... Read More

Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides... Read More

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space (SCS ® ) Delivery Platform ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the... Read More

ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a... Read More

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside’s Board as an independent director in April 2024,... Read More

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference... Read More

CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) Versatility of SCS Microinjector ® Featured in Multiple Presentations ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company... Read More

Maintained Stable Visual Acuity and Anatomical Control Over 9 Months Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months Reduced Treatment Burden by 84% Over 6 Months Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg,... Read More

CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector ® Topline Data Expected to be Reported During the Week of October 7, 2024 ALPHARETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®... Read More

Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and Real-World Experience of Suprachoroidal Drug Delivery ALPHARETTA, Ga., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a... Read More

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced that management will present a corporate update at the H.C. Wainwright 4 th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00... Read More

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference... Read More

ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced that its partner, Arctic Vision, reported positive topline results from its Phase 3 clinical trial of ARCATUS ® (ARVN001) for the treatment of Uveitic Macular Edema (UME) in China. In... Read More

ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. To register for the event, click here . The event will highlight the broad... Read More

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of... Read More

Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of... Read More

Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector ® ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that... Read More

Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the... Read More

Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 Strengthened Management Team and Board of Directors with Two Key Additions Management to Host Webcast and Conference Call Today at 4:30 P.M. ET ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the... Read More

ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens... Read More

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call... Read More

ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. “We are delighted to welcome Tony to our Board of Directors as we build on... Read More

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23 r d... Read More

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024. Dr. Chong is a board-certified retinal specialist with more than 25 years of experience as a... Read More

Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector ® Strengthened Capital Position from Registered Direct Equity Offering and Recent SCS Microinjector License Agreement Management to Host Webcast and Conference Call Today at 4:30 P.M. ET ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside... Read More

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and... Read More

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale... Read More

CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector ® Randomization Completed in ODYSSEY Phase 2b Clinical Trial Topline Data Expected in Q3 2024 ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space... Read More

New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales Based Milestone Payments, Plus Royalties Recruitment Completed in CLS-AX Phase 2b ODYSSEY Wet AMD Trial with Topline Data Expected in Q3 2024... Read More

ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15,... Read More

ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral and poster presentations were delivered at the Annual Meeting of the American Academy of Ophthalmology (AAO) that highlighted encouraging safety and efficacy data... Read More

ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting taking place November 3 – 6, 2023 in San Francisco,... Read More

Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support Topline Data Expected in Q3 2024 ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the completion of recruitment in its... Read More

ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets. Management will host a webcast and conference... Read More

Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ),... Read More

Continued Progress in the Global Development and Commercialization of XIPERE ® (known as ARCATUS ® in China) ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment... Read More

ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm... Read More

ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference on Tuesday, September... Read More

Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings Management to Host Webcast and Conference Call Today at 4:30 P.M. ET ALPHARETTA, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company... Read More

ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc . (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced that management will participate in the following investor conferences in August 2023: Chardan Virtual Ophthalmology Summit Age-Related Macular Degeneration and Diabetes-Related Eye... Read More

ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its second quarter 2023 financial results will be reported on Monday, August 14, 2023 after the close of the financial markets. Management will host a webcast and conference... Read More

Suprachoroidal Injection of CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months ALPHARETTA, Ga., July 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that safety and tolerability data from its recent OASIS clinical... Read More

ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that presentations will be delivered at the American Society of Retina Specialists (ASRS) 41 st Annual Scientific Meeting and the Ophthalmology Innovation Source (OIS) Retina... Read More

Evaluating CLS-AX as a Potential Twice-a-Year Therapy Trial Progressing with Topline Results Expected in Q3 2024 ALPHARETTA, Ga., July 17, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the enrollment and dosing of participants is underway in... Read More

ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer, will present at the SHARE™ Series Monday Management Update for investors on Monday, July 17,... Read More

XIPERE ® is referred to as Arcatus (ARVN001) by Arctic Vision ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced that the Therapeutic Goods Administration (TGA) of Australia has formally accepted Arctic Vision’s new drug application (NDA)... Read More

U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD ODYSSEY Topline Results Expected in Q3 2024 ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical... Read More

Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings Management to Host Webcast and Conference Call Today at 8:30 A.M. ET ALPHARETTA, Ga., May 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a... Read More

ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Tuesday, May 16,... Read More

ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023 before the open of the financial markets. Management will host a webcast and conference call... Read More

ALPHARETTA, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that several key poster presentations were delivered on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO)... Read More

ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple poster presentations will be given on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023... Read More

Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter ODYSSEY Topline Results Expected in Q3 2024 ALPHARETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today plans for ODYSSEY, a randomized, double-masked,... Read More

ALPHARETTA, Ga., April 12, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 22 nd Annual Needham Virtual Healthcare Conference on... Read More

ALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), today announced the appointment of Arshad M. Khanani, M.D., M.A, F.A.S.R.S and Lejla Vajzovic, M.D., F.A.S.R.S to its Scientific Advisory Board (SAB). Clearside’s SAB is comprised of industry... Read More

Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months Continued Growth in Retinal Specialists Trained in Suprachoroidal Space (SCS ® ) Injection Procedure Using FDA-Approved XIPERE ® Management to Host Webcast and Conference Call Today at... Read More

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and... Read More

CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders SCS Microinjector ® Featured in Favorable Data Presentations Related to Multiple Therapies in Clinical Development ALPHARETTA, Ga., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to... Read More

ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that data from the Company’s OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) will be presented at the following medical meetings in February 2023:... Read More

ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down... Read More

Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key... Read More